tility of rivaroxaban for chronic disseminated intravascular coagulatio
Not Applicable
Recruiting
- Conditions
- chronic disseminated intravascular coagulation
- Registration Number
- JPRN-UMIN000020617
- Lead Sponsor
- Hidesaku Asakura, Kanazawa University School of Medicine.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with a history or serious drug allergy. 2. Patients with severe renal failure. 3. The patient, who are at risk of promoting the bleeding by administration of rivaroxaban. 4. The patients, who are presumed to die soon even though DIC is improvred. 5. The patients, who are pregnant, likely to be pregnant or breast-feeding. 6. The patients, who are not judged suitable for study patients by investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety of rivaroxaban in treatment for chronic DIC (bleeding and thrombotic symptoms are estimated at 2w, 1M, 3M, 6M, 12M, 2y, 3y, 4y and 5y)
- Secondary Outcome Measures
Name Time Method effectiveness of rivaroxaban in treatment for chronic DIC